Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Alto's phase 2 depression trial misses primary efficacy endpoint
Patients on the drug candidate fared no better on a measure of alertness and mood than their peers on placebo.
Nick Paul Taylor
Jun 26, 2025 9:28am
MindRank reports 10% weight loss on oral GLP-1 drug in phase 2b
Jun 24, 2025 10:06am
Nektar stock doubles as phase 2b eczema trial hits endpoints
Jun 24, 2025 9:20am
BrightGene tops Novo drug in diabetes ahead of Zepbound showdown
Jun 23, 2025 2:30pm
Exelixis beats Bayer drug in cancer trial, sending stock higher
Jun 23, 2025 7:30am
Novo's injectable amycretin yet to hit weight loss plateau
Jun 23, 2025 4:29am
